Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro

doi:10.4251/wjgo.121282

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 9

This Article

(5)

(7)

(0)

(29)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Sep 15, 2026; 18(9): 121282
Published online Sep 15, 2026. doi: 10.4251/wjgo.121282

Full Size Figure Download Figure

Figure 2 The effect of cyclin-dependent kinase 6 on the proliferation of gastrointestinal stromal tumor cells. The effect of cyclin-dependent kinase 6 inhibitors on the proliferation of T1, 882, and 430 cell lines: T1 vs T1 + palbociclib (P), T1 + ripretinib (Ri) vs T1 + Ri + P (P > 0.05), 882 vs 882 + P, 882 + Ri vs 882 + Ri + P (P > 0.05), 430 vs 430 + P, 430 + Ri vs 430 + Ri + P (P > 0.05). The effect of cyclin-dependent kinase 6 inhibitors on the proliferation of T1 resistance index (RI), 882RI, and 430RI cell lines: T1RI vs T1RI + P, T1RI + Ri vs T1RI + Ri + P (P < 0.05), 882RI vs 882RI + P, 882RI + Ri vs 882RI + Ri + P (P < 0.05) and 430RI vs 430RI + P, 430RI + Ri vs 430RI + Ri + P (P < 0.05). ^aP < 0.05. P: Palbociclib; Ri: Ripretinib; RI: Resistance index.

Citation: Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR. Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro. World J Gastrointest Oncol 2026; 18(9): 121282
URL: https://www.wjgnet.com/1948-5204/full/v18/i9/121282.htm
DOI: https://dx.doi.org/10.4251/wjgo.121282

Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR. Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro. World J Gastrointest Oncol 2026; 18(9): 121282 [DOI: 10.4251/wjgo.121282]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.